2017. Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study. Farmeconomia. Health economics and therapeutic pathways. 18, 1 (Oct. 2017). DOI:https://doi.org/10.7175/fe.v18i1.1332.